CClinicalTrials.gg
CompletedNCT04882800Updated Dec 14, 2022Results posted

Evaluation of Extended Wear Technology

An interventional study of Lyric extended wear hearing aid device A and Lyric extended wear hearing aid with fitting modification device B in Hearing Loss, sponsored by Sonova AG. Completed at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Sonova AG · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Evaluating the efficacy and effectiveness of an advancement in the fitting characteristics of extended wear technology with the commercially available device as a comparator.

Read the detailed description

A interventional study in which participants will be fit with the commercially available device in one ear and the experimental device in the opposite ear. After two weeks, the devices will be switched so that the participant has worn each device in each ear for a total of 2 weeks. Participants will be blinded as to which device they are wearing in each ear. Comfort and sound quality will be assessed for each device prior to removing from ears.

02

Conditions studied

  • Hearing Loss

Browse trials for

03

In context

Hearing Loss

1,092 studies on the registry are indexed under Hearing Loss; 235 are open to participants now.

This study's enrollment of 15 is below the median of 40 across 764 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

Sonova AG is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 17 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Mild, Moderate and Moderate Severe Hearing loss
  • Previous extended wear technology users who rejected or cancelled trials due to discomfort, feedback, migration, or poor sound quality due to fit issues

Exclusion criteria

Exclusion Criteria:

  • Participants who can only wear a size XXS (extra-extra small) extended wear device
  • asymmetrical hearing loss
  • other diagnosis that may cause hearing fluctuation
  • inability to tolerate physical fit of Lyric devices
  • inability to be seen for four lab visits
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    First Intervention

    Participants will be fit with currently available Lyric extended wear hearing aid device A in right ear and Lyric extended wear hearing aid with fitting modification device B in left ear for 14 days (Day 1 - Day 14 of study). They will then switch and be fit with Lyric extended wear hearing aid with fitting modification device B in the right ear and the commercially available Lyric device A in the left ear for 14 days (Day 15-Day 28 of study)

    Device: Lyric extended wear hearing aid device A · Device: Lyric extended wear hearing aid with fitting modification device B

Interventions

  • DeviceLyric extended wear hearing aid device A

    Current commercially available extended wear hearing aid

  • DeviceLyric extended wear hearing aid with fitting modification device B

    Extended wear hearing aid with fitting modifications

06

What researchers measure

Primary outcomes

  1. Subjective Questionnaire of Comfort

    Subjective ratings of comfort of each device in the ear, on a scale from 0 (very comfortable) to 10 (very uncomfortable/painful). No statistical analysis was planned for this measure.

    Time frame: Two weeks after fitting device A in right ear/device B in left ear (Day 14 of study), and two weeks after fitting device A in left ear/device B in right ear (Day 28 of study-final appointment)

  2. Subjective Ratings of Occlusion With Both Devices

    Subjective ratings on how plugged participants' ears felt with each device in ear,on scale from 0 (not at all) to 10 (extremely plugged/cannot tolerate)

    Time frame: Two weeks after fitting device A in right ear/device B in left ear (Day 14 of study), and two weeks after fitting device A in left ear/device B in right ear (Day 28 of study-final appointment)

07

Results

Posted Dec 14, 2022

Participant flow

Device A Right Ear/Device B Left Ear
Participant flow — Device A Right Ear/Device B Left Ear
MilestoneIntervention
Started15
Completed15
Not completed0
Device B Right Ear/Device A Left Ear
Participant flow — Device B Right Ear/Device A Left Ear
MilestoneIntervention
Started15
Completed15
Not completed0

Outcome measures

PrimarySubjective Questionnaire of Comfort

Subjective ratings of comfort of each device in the ear, on a scale from 0 (very comfortable) to 10 (very uncomfortable/painful). No statistical analysis was planned for this measure.

Time frame:
Two weeks after fitting device A in right ear/device B in left ear (Day 14 of study), and two weeks after fitting device A in left ear/device B in right ear (Day 28 of study-final appointment)
Reported as:
Median · score on a scale
Subjective Questionnaire of Comfort
score on a scaleIntervention
Comfort Rating of Device A0 (0 to 7)
Comfort Rating of Device B (investigational device)0 (0 to 10)
PrimarySubjective Ratings of Occlusion With Both Devices

Subjective ratings on how plugged participants' ears felt with each device in ear,on scale from 0 (not at all) to 10 (extremely plugged/cannot tolerate)

Time frame:
Two weeks after fitting device A in right ear/device B in left ear (Day 14 of study), and two weeks after fitting device A in left ear/device B in right ear (Day 28 of study-final appointment)
Reported as:
Median · score on a scale
Subjective Ratings of Occlusion With Both Devices
score on a scaleIntervention
Occlusion Rating with Device A0 (0 to 8)
Occlusion Rating with Device B (fitting modification)0 (0 to 10)

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Intervention (Device A in Right Ear and Device B in Left Ear)0/15 (0%)0/15 (0%)0/15 (0%)
Second Intervention (Device B in Right Ear and Device A in Left Ear)0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Experienced hearing aid users

Age, Continuous
Age, Continuous(years)All Study Participants
Mean68 (34 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female8
Male7
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Study Participants
Region of Enrollment
Region of Enrollment(participants)All Study Participants
United States15
08

Study locations

1 site
  • Main Line Audiology Consultants
    Narberth, Pennsylvania 19072, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 20, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Data will not be shared

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04882800
Lead sponsor
Sonova AG
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Apr 8, 2021
Primary completion
May 31, 2021
Completion
Jun 15, 2021
Results posted
Dec 14, 2022
Last update
Dec 14, 2022

Study contacts

Kevin Seitz-Paquette, AuD
principal investigator · Sonova AG

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion